Curated News
By: NewsRamp Editorial Staff
March 12, 2026
Aclarion CEO to Showcase AI-Powered Back Pain Tech at LSI USA 2026
TLDR
- Aclarion's CEO attending LSI USA 2026 offers investors early access to their AI-powered Nociscan platform for chronic back pain diagnosis.
- Aclarion's Nociscan platform uses MR spectroscopy, biomarkers, and AI algorithms to analyze disc chemistry and identify painful versus non-painful spinal discs.
- Aclarion's technology helps physicians accurately diagnose chronic back pain, potentially improving treatment outcomes and reducing patient suffering through non-invasive methods.
- Aclarion combines MRI spectroscopy with AI to create a cloud-based system that chemically analyzes spinal discs for pain biomarkers.
Impact - Why it Matters
This news matters because chronic low back pain is a debilitating condition affecting over 500 million people globally, often leading to misdiagnosis, ineffective treatments, and reduced quality of life. Aclarion's Nociscan technology addresses this by providing objective, biomarker-based insights that help physicians accurately identify painful discs, potentially reducing unnecessary surgeries and improving patient outcomes. By participating in LSI USA 2026, Aclarion is positioning itself to secure partnerships and funding that could accelerate the adoption of this innovative tool, making it more accessible to healthcare providers and patients. This advancement represents a shift toward personalized, data-driven medicine, offering hope for more effective management of a widespread and costly health issue.
Summary
In a significant development for the medical technology sector, Aclarion, Inc., a commercial-stage healthcare technology company, has announced that its CEO Brent Ness will be attending the prestigious LSI USA 2026 conference in Dana Point, California, from March 16-20. The event, a premier gathering for MedTech and HealthTech innovators, investors, and industry leaders, will serve as a crucial platform for Ness to engage in one-on-one meetings with potential investors and partners. This strategic move underscores Aclarion's commitment to advancing its groundbreaking Nociscan platform, a proprietary MR spectroscopy system that leverages biomarkers and augmented intelligence algorithms to help physicians pinpoint the source of chronic low back pain—a condition affecting millions worldwide.
At the core of Aclarion's mission is Nociscan, the first evidence-supported SaaS platform designed to noninvasively distinguish between painful and non-painful discs in the lumbar spine. By analyzing magnetic resonance spectroscopy data through cloud-based proprietary signal processing, Nociscan extracts chemical biomarkers associated with disc pain, providing physicians with critical insights to optimize treatment strategies. This technology represents a paradigm shift in diagnosing chronic low back pain, offering a more precise alternative to traditional methods. For more information on Nociscan, interested parties can visit the company's website or contact them via email, and to find a Nociscan center, view the site map available through the provided link.
The announcement, distributed via PRISM MediaWire, a trusted press release distribution service, highlights Aclarion's proactive approach to forging industry connections and driving innovation. With chronic low back pain being a leading cause of disability globally, Aclarion's efforts to enhance diagnostic accuracy could revolutionize patient care. Investors and media can access further updates through the company's newsroom or by contacting the provided investor and media contacts. This news not only showcases Aclarion's growth trajectory but also emphasizes the broader impact of AI-driven healthcare solutions in addressing pervasive medical challenges.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, Aclarion CEO to Showcase AI-Powered Back Pain Tech at LSI USA 2026
